AR072697A1 - PIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF PLATQUETARY AGGREGATION DISORDER - Google Patents
PIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF PLATQUETARY AGGREGATION DISORDERInfo
- Publication number
- AR072697A1 AR072697A1 ARP090102523A ARP090102523A AR072697A1 AR 072697 A1 AR072697 A1 AR 072697A1 AR P090102523 A ARP090102523 A AR P090102523A AR P090102523 A ARP090102523 A AR P090102523A AR 072697 A1 AR072697 A1 AR 072697A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- ring
- heterocyclyl
- cycloalkyl
- aryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000002776 aggregation Effects 0.000 title 1
- 238000004220 aggregation Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 8
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 3
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 abstract 3
- 229910052794 bromium Inorganic materials 0.000 abstract 3
- 229910052801 chlorine Inorganic materials 0.000 abstract 3
- 125000004122 cyclic group Chemical group 0.000 abstract 3
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 3
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000005366 cycloalkylthio group Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- -1 iminomethylene Chemical group 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000005110 aryl thio group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000005429 oxyalkyl group Chemical group 0.000 abstract 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Reivindicacion 1: Un compuesto de la formula (1) o una sal farmacéuticamente aceptable del mismo; donde R1 representa R7C(O); R2 representa alquiltio C1-3 insustituido o hidroxialquil C1-3 insustituido; R7 representa alquil C1-3 opcionalmente interrumpido por oxígeno, y/o opcionalmente sustituido por OH, arilo, cicloalquil C3-6, heterociclil o uno o más átomos de halogeno (F, Cl, Br, l); además R7 representa cicloalquil C3-6, hidroxialquil C1-12, aril o heterociclil; R14 representa H, OH con la condicion de que el grupo OH debe estar al menos 2 átomos de carbono separado de cualquier heteroátomo en el sistema de anillo/anillo B, alquil C1-8 opcionalmente interrumpido por oxígeno y/o opcionalmente sustituido por uno o más OH, COOH y COORe donde Re representa aril, cicloalquil C3-6, heterociclil o alquil C1-8 opcionalmente sustituido por uno o más átomo(s) de halogeno (F, CI, Br, l), OH, aril, cicloalquil C3-6 y heterociclil; además R14 representa aril, arilalquil C1-8, arilalcoxi C1-3, heterociclil, un átomo de halogeno (F, CI, Br, l), cicloalquil C3-6, cicloalquil C3-6alcoxi C1-8, hidroxialquil C1-8, alcoxi C1-8, cicloalcoxi C3-6, alquilsulfinil C1-8, alquilsulfonil C1-8, alquiltio C1-8, cicloalquiltio C3-6, o un grupo de la formula NRa(14)Rb(14) en la cual Ra(14) y Rb(14) independientemente representan H, alquil C1-8, alquil-C(O) C1-8, alcoxi-C(O) C1-8 o Ra(14) y Rb(14) junto con el átomo de nitrogeno representan piperidina, pirrolidina, azetidina o aziridina; Rc es un enlace directo o representa un grupo alquileno C1-4 insustituido o monosustituido o polisustituido, donde cualesquiera sustituyentes cada uno individual e independientemente son seleccionados de alquil C1-4, alcoxil C1-4, oxi-alquil C1-4, alquenil C2-4, alquinil C2-4, cicloalquil C3-6, carboxil, carboxialquil C1-4, aril, heterociclil, ciano, halogeno (F, Cl, Br, l), hidroxil, NRa(Rc)Rb(Rc) en la cual Ra(Rc) y Rb(Rc) individual e independientemente uno del otro representan hidrogeno, alquil C1-4 o Ra(Rc) y Rb(Rc) junto con el átomo de nitrogeno representan piperidina, pirrolidina, azetidina o aziridina; además Rc representa imino (-NH-), imino N sustituido (-NR19-), alquilenoimino C1-4 o alquilenoimino C1-4 N-sustituido (-N(R19)-alquileno C1-4) donde los grupos alquileno mencionados son insustituidos o monosustituidos o polisustituidos con cualesquiera sustituyentes de acuerdo con lo anterior; R19 representa H o alquil C1-4; Rd representa alquil C1-12, cicloalquil C3-8, aril o heterociclil, y cualquiera de estos grupos opcionalmente sustituido con uno o más átomos de halogeno (F, Cl, Br, l) o átomos de halogeno mezclados y/o uno o más de los siguientes grupos, OH, CN, alquil C1-12, alcoxi-C(O) C1-12, alcoxi C1-12, alquil C1-12 sustituido con halogeno, cicloalquil C3-6, aril, heterociclil, alquilsulfinil C1-12, alquilsulfonil C1-12, alquiltio C1-12, cicloalquiltio C3-6, arilsulfinil, arilsulfonil, ariltio, arilalquiltio C1-12, arilaIquiIsulfinil C1-12, ariIalquilsulfonil C1-12, heterociclilalquiltio C1-12, heterociclilalquilsulfinil C1-12, heterociclilalquilsulfonil C1-12, cicloalquil C3-6alquiltio C1-12, cicloalquil C3-6alquilsulfinil C1-12, cicloalquil C3-6alquilsulfonil C1-12 o un grupo de la formula NRa(Rd)Rb(Rd) en la cual Ra(Rd) y Rb(Rd) independientemente representan H, alquil C1-12, alquil-C(O) C1-12 o Ra(Rd) y Rb(Rd) junto con el átomo de nitrogeno representan piperidina, pirrolidina, azetidina o aziridina; X representa un enlace simple, imino (-NH-), metileno (-CH2-), iminometileno (-CH2-NH-) donde el carbono está conectado al sistema de anillo/anillo B, metilenoimino (-NH-CH2-) donde el nitrogeno está conectado al sistema de anillo/anillo B y cualquier carbono y/o nitrogeno en estos grupos puede ser opcionalmente sustituido con alquil C1-6; además X puede representar un grupo (-CH2-)n donde n = 2-6, el cual opcionalmente es insaturado y/o sustituido por uno o más sustituyentes escogidos entre halogeno, hidroxil o alquil C1-6; y B es un sistema de anillo/anillo heterocíclico de 4 a 11 miembros, monocíclico o bicíclico que comprende uno o más nitrogenos y opcionalmente uno e más átomos seleccionados de oxígeno o azufre, dicho nitrogeno es conectado al anillo de piridina (de acuerdo con la formula (1)) y además el sistema de anillo/anillo B es conectado a X en otra de sus posiciones; el sustituyente R14 es conectado al sistema de anillo/anillo B de manera tal que no se forman compuestos de amonio cuaternario (por esta conexion).Claim 1: A compound of the formula (1) or a pharmaceutically acceptable salt thereof; where R1 represents R7C (O); R2 represents unsubstituted C1-3 alkylthio or unsubstituted C1-3 hydroxyalkyl; R7 represents C1-3 alkyl optionally interrupted by oxygen, and / or optionally substituted by OH, aryl, C3-6 cycloalkyl, heterocyclyl or one or more halogen atoms (F, Cl, Br, l); R7 also represents C3-6 cycloalkyl, C1-12 hydroxyalkyl, aryl or heterocyclyl; R14 represents H, OH with the proviso that the OH group must be at least 2 carbon atoms separated from any heteroatom in the ring / ring B system, C1-8 alkyl optionally interrupted by oxygen and / or optionally substituted by one or plus OH, COOH and COORe where Re represents aryl, C3-6 cycloalkyl, heterocyclyl or C1-8 alkyl optionally substituted by one or more halogen atom (s) (F, CI, Br, l), OH, aryl, C3 cycloalkyl -6 and heterocyclyl; R14 also represents aryl, C1-8 arylalkyl, C1-3 arylalkoxy, heterocyclyl, a halogen atom (F, CI, Br, l), C3-6 cycloalkyl, C3-6alkoxy C1-8 alkoxy, C1-8 hydroxyalkyl, alkoxy C1-8, C3-6 cycloalkoxy, C1-8 alkylsulfinyl, C1-8 alkylsulfonyl, C1-8 alkylthio, C3-6 cycloalkylthio, or a group of the formula NRa (14) Rb (14) in which Ra (14) and Rb (14) independently represent H, C1-8 alkyl, C-alkyl (O) C1-8, alkoxy-C (O) C1-8 or Ra (14) and Rb (14) together with the nitrogen atom represent piperidine, pyrrolidine, azetidine or aziridine; Rc is a direct bond or represents an unsubstituted or monosubstituted or polysubstituted C1-4 alkylene group, where any substituents each individually and independently are selected from C1-4 alkyl, C1-4 alkoxy, C1-4 oxy-alkyl, C2 alkenyl 4, C2-4 alkynyl, C3-6 cycloalkyl, carboxy, C1-4 carboxyalkyl, aryl, heterocyclyl, cyano, halogen (F, Cl, Br, l), hydroxyl, NRa (Rc) Rb (Rc) in which Ra (Rc) and Rb (Rc) individually and independently of each other represent hydrogen, C1-4 alkyl or Ra (Rc) and Rb (Rc) together with the nitrogen atom represent piperidine, pyrrolidine, azetidine or aziridine; Rc also represents imino (-NH-), imino N substituted (-NR19-), C1-4 alkyleneimino or C1-4 N-substituted alkyleneimino (-N (R19) -C 1-4 alkylene) where the mentioned alkylene groups are unsubstituted or monosubstituted or polysubstituted with any substituents in accordance with the foregoing; R19 represents H or C1-4 alkyl; Rd represents C1-12 alkyl, C3-8 cycloalkyl, aryl or heterocyclyl, and any of these groups optionally substituted with one or more halogen atoms (F, Cl, Br, l) or mixed halogen atoms and / or one or more of the following groups, OH, CN, C1-12 alkyl, C-C (O) C1-12 alkoxy, C1-12 alkoxy, halogen substituted C1-12 alkyl, C3-6 cycloalkyl, aryl, heterocyclyl, C1-12 alkylsulfinyl , C1-12 alkylsulfonyl, C1-12 alkylthio, C3-6 cycloalkylthio, arylsulfinyl, arylsulfonyl, arylthio, C1-12 arylalkyl, arylaIquiIsulfinyl C1-12, ariIalkylsulfonyl C1-12, heterocyclyl-alkylthio C1-12, heterocyclyl-Cyl-alkylsylfinyl-cyl-cyl-alkylsulffin 12, C3-6 cycloalkyl C1-12alkylthio, C3-6alkylcycloalkyl C1-12, cycloalkylC3-6alkyl sulfonyl C1-12 or a group of the formula NRa (Rd) Rb (Rd) in which Ra (Rd) and Rb (Rd ) independently represent H, C1-12 alkyl, C-C (O) C1-12 alkyl or Ra (Rd) and Rb (Rd) together with the nitrogen atom represent piperidine, pyrrolidine, azetidin a or aziridine; X represents a simple bond, imino (-NH-), methylene (-CH2-), iminomethylene (-CH2-NH-) where carbon is connected to the ring / ring B system, methyleneimino (-NH-CH2-) where the nitrogen is connected to the ring / ring B system and any carbon and / or nitrogen in these groups can be optionally substituted with C1-6 alkyl; X can also represent a group (-CH2-) n where n = 2-6, which is optionally unsaturated and / or substituted by one or more substituents chosen from halogen, hydroxyl or C1-6 alkyl; and B is a 4 to 11-membered, monocyclic or bicyclic heterocyclic ring / ring system comprising one or more nitrogen and optionally one and more atoms selected from oxygen or sulfur, said nitrogen is connected to the pyridine ring (according to the formula (1)) and in addition the ring / ring system B is connected to X in another of its positions; substituent R14 is connected to the ring / ring system B so that no quaternary ammonium compounds are formed (by this connection).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7848008P | 2008-07-07 | 2008-07-07 | |
| US12201608P | 2008-12-12 | 2008-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072697A1 true AR072697A1 (en) | 2010-09-15 |
Family
ID=41507301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102523A AR072697A1 (en) | 2008-07-07 | 2009-07-06 | PIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF PLATQUETARY AGGREGATION DISORDER |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR072697A1 (en) |
| WO (1) | WO2010005384A1 (en) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009501216A (en) * | 2005-07-13 | 2009-01-15 | アストラゼネカ アクチボラグ | New pyridine analogues |
| TW200815426A (en) * | 2006-06-28 | 2008-04-01 | Astrazeneca Ab | New pyridine analogues II 333 |
| WO2008004945A1 (en) * | 2006-07-04 | 2008-01-10 | Astrazeneca Ab | Novel crystalline forms i and ii |
| TW200811133A (en) * | 2006-07-04 | 2008-03-01 | Astrazeneca Ab | New pyridine analogues III 334 |
| WO2008004944A1 (en) * | 2006-07-04 | 2008-01-10 | Astrazeneca Ab | Novel crystalline form ii |
| WO2008085119A1 (en) * | 2007-01-12 | 2008-07-17 | Astrazeneca Ab | New pyridine analogues viii 518 |
| RU2009123928A (en) * | 2007-01-12 | 2011-02-20 | Астразенека Аб (Se) | PYRIDINE COMPOUNDS AND THEIR APPLICATION AS P2Y12 ANTAGONISTS |
-
2009
- 2009-07-06 AR ARP090102523A patent/AR072697A1/en unknown
- 2009-07-06 WO PCT/SE2009/050875 patent/WO2010005384A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010005384A1 (en) | 2010-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061651A1 (en) | PIRIDINE ANALOGS II | |
| AR059279A1 (en) | DERIVATIVES OF TRICYCLE N-HETEROARIL-CARBOXAMIDS CONTAINING A REST BENCIMIDAZOL, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | |
| AR060605A1 (en) | DERIVATIVES OF DIAZEPAN AS ANTAGONISTS OF THE CCR2 RECEIVER | |
| AR045752A1 (en) | QUINAZOLINE DERIVATIVES THAT HAVE ANTITUMORAL ACTIVITY | |
| AR070207A1 (en) | BICYCLE DERIVATIVES OF CARBOXAMIDAS AZA- BICICLICAS ITS PREPARATION AND ITS THERAPEUTIC APPLICATION | |
| AR070992A1 (en) | DERIVATIVES OF 2-ARIL-6-FENIL-INIDAZO [1,2A] PIRIDINAS, ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS AND ITS USE IN DISEASES THAT INVOLVE NURLE-1 NUCLEAR RECEPTORS | |
| AR045762A1 (en) | QUINAZOLINE DERIVATIVES | |
| PE20120031A1 (en) | ARYL METHYL BENZOQUINAZOLINONE COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF THE M1 RECEPTOR | |
| AR060658A1 (en) | DICETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | |
| AR064619A1 (en) | DERIVATIVES OF AMINO-IMIDAZOPIRIDINAS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES OF THE SAME AS ANTITUMORAL AGENTS. | |
| AR070995A1 (en) | POLISUSTITUTED DERIVATIVES OF 6-HETEROARIL-IMIDAZO [1,2-A] PIRIDINA, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESS OF THE SAME, INTERMEDIARIES OF SYNTHESIS AND USE OF THE SAME IN THE TREATMENT OR PREVENTION OF NURSING -1, SUCH AS ENFE | |
| PE20130306A1 (en) | MORPHOLINOPYRIMIDINES AND THEIR USE IN THERAPY | |
| AR037907A1 (en) | DERIVATIVES OF AZAINDOLILALQUILAMINA AS 5-HYDROXYTHYRIPTAMINE-6 LIGANDS | |
| AR040567A1 (en) | DERIVATIVES OF 1- HETEROCICLILALQUIL 3- SULFONYLINDOL OR -INDAZOL AS 5-HYDROXYTHYRIPTAMINE -6 LIGANDS | |
| AR043181A1 (en) | HETEROCICLIL-3-SULPHONYLINDAZOLS AS LIGANDS OF 5-HYDROXYPTAMINE-6 | |
| AR040048A1 (en) | DERIVATIVES OF 1- (AMINOALQUIL) -3-SULFONYLINDOL AND INDAZOL AS LIGANDS OF 5-HYDROXYTHYRIPTAMINE-6 | |
| AR069813A1 (en) | DERIVATIVES OF 2- AMINO-PYRIMIDINE, A PHARMACEUTICAL COMPOSITION, A METHOD OF PREPARATION OF THE COMPOUND AND USE OF IT TO PREPARE A MEDICINAL PRODUCT | |
| AR068466A1 (en) | CYANOISOQUINOLINE | |
| AR060593A1 (en) | 5-AMIDO-2-CARBOXIAMIDA-INDOLES | |
| AR056197A1 (en) | DERIVATIVES OF 7-METHYLIMIDAZOL [1,2-A] PIRIDIN-6-IL-8-METHYL-NONAMIDS AS INHIBITORS OF THE RENIN, PHARMACEUTICAL COMPOSTIONS CONTAINING THEM AND THEIR USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF ARTERIAL HYPERTENSION | |
| AR053092A1 (en) | COMPOUNDS DERIVED FROM PHENOXYACETIC ACID AND INTERMEDIATE SYNTHESIS COMPOUNDS | |
| AR077301A1 (en) | DERIVATIVES OF 2-CARBOXAMIDA-7-PIPERAZINIL-BENZOFURAN AS ANTAGONISTS OF 5-HT1A AND 5-HT1B | |
| PE20050231A1 (en) | DERIVATIVES OF PIPERIDINIUM AND PYRROLIDINIUM AS ANTAGONISTS OF THE MUSCARINIC M3 RECEPTOR | |
| MX9206169A (en) | DERIVATIVES OF QUINOLEIN, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS. | |
| AR064866A1 (en) | PIRIDINE ANALOGS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |